Dissemination | Physician's Weekly
Advertisement

Dissemination

Non-Pharmaceutical Alternatives for Patients With GERD

We recently spoke with Raman Muthusamy, MD, MAS, professor of medicine and medical director of endoscopy at UCLA Health, about current treatment alternatives for patients with GERD who are either failing medical treatment or...

Sex Differences in Anti-PD-1/Anti-PD-L1 Treatment for NSCLC

For the treatment of non-small cell lung cancer (NSCLC), anti-PD-1/anti-PD-L1 monotherapy is highly effective in men but not in women, even in NSCLC that expresses high PD-L1 levels, explain Fabio Conforti, MD, and Laura Pala,...

Postoperative Nutrition May Affect Early-Stage NSCLC Outcomes

Postoperative changes in nutritional status may be important in early-stage NSCLC outcomes, according to a study published in PLoS One. Although preoperative nutritional status is an important host-related prognostic factor for...

Atezolizumab Favorable After Adjuvant Chemotherapy

Atezolizumab after adjuvant chemotherapy offers a promising treatment option for patients with resected early-stage NSCLC, according to a study published in The Lancet. Researchers who evaluated adjuvant atezolizumab versus best...

Pediatric Use Of Omalizumab For Allergic Asthma

Clinical trials and observational studies have demonstrated that omalizumab is safe and effective for treating pediatric asthma. However, further research must be conducted to determine the potential benefits of anti-IgE...

Mast Cells and Their Progenitors in Allergic Asthma

This review summarizes research on mast cells, and the implications of the role and development of mast cells in allergic asthma. The study focuses on the progenitors of mast cells in allergic asthma as well as selected...

Larger Studies In Asthma And Allergic Disease Genetics

Larger studies are needed focusing on genome-wide association studies (GWASs) of asthma and allergic diseases, especially in the patients with childhood-onset asthma and allergic diseases group, and in African American and...

Loading

Advertisement

For latest news and updates
Email-id is invalid